Comprehensive study provides new understandings of genomic influences on neuropsychiatric disease

FHS
May 24, 2024
3:30 am

A new analysis has revealed detailed information about genetic variation in brain cells that could open new avenues for the targeted treatment of diseases such as schizophrenia and Alzheimer’s disease.

Dr. Dominik Kugelstadt joins as Head of Clinical and Commercial Manufacturing, Laupheim – Biotech Investments

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel Rentschler Biopharma SE : Dr. Dominik Kugelstadt joins as Head of Clinical and Commercial Manufacturing, Laupheim 12.07.2023

July 13, 2023

PhRMA sues Biden administration over Medicare drug price negotiation program

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts. The pharmaceutical industry’s biggest lobbying group on

June 21, 2023

Sanofi’s Mourenx production site leaked a potentially cancerous neurotoxin for the second time

Sanofi’s chemical production facility in Mourenx, France, is under scrutiny again after leaking an excess of the neurotoxin bromopropane, having been temporarily shut down five

December 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.